| URL | https://www.biopharma-reporter.com/Article/2022/09 |
| Source | Bio Pharma |
| Date Published | 09/06/2022 |
| Author Name | Jane Byrne |
| Mentions specific company case(s) of reshoring, kept from offshoring, or transplant | Yes |
| Company/Division name | Ori Biotech |
| Parent company | Ori Biotech Limited |
| Type of work | Manufacturing |
| Reshoring category: | Foreign Direct Investment |
| Year reshoring announced: | 2022 |
| Country(ies) from which reshored: | United Kingdom |
| City reshored to: | Princeton |
| State(s) reshored to: | NJ |
| If relevant, work nearshored to: | - |
| Industry(ies): | Chemicals |
| Product(s) reshored | cell and gene therapy |
| What domestic positive factors made reshoring more attractive? | Lead time/Time to market, Skilled workforce availability/training |